These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 31382304)

  • 1. Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.
    Arachchillage DR; Laffan M
    Semin Thromb Hemost; 2019 Sep; 45(6):604-611. PubMed ID: 31382304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms.
    De Stefano V; Finazzi G; Barbui T
    Blood Cancer J; 2018 Jun; 8(7):65. PubMed ID: 29946112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Thrombosis in myeloproliferative neoplasms].
    Asakura H
    Rinsho Ketsueki; 2018; 59(8):1034-1041. PubMed ID: 30185703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018.
    Finazzi G; De Stefano V; Barbui T
    Blood Cancer J; 2018 Jun; 8(7):64. PubMed ID: 29946154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulants.
    How J; Story C; Connors JM
    Postgrad Med; 2021 Jun; 133(5):508-516. PubMed ID: 33480813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms.
    Hamulyák EN; Daams JG; Leebeek FWG; Biemond BJ; Te Boekhorst PAW; Middeldorp S; Lauw MN
    Blood Adv; 2021 Jan; 5(1):113-121. PubMed ID: 33570633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombosis in myeloproliferative neoplasms: Treatment outcomes of direct oral anticoagulants and vitamin K antagonists.
    Fedorov K; Goel S; Kushnir M; Billett HH
    Res Pract Thromb Haemost; 2021 Aug; 5(6):e12574. PubMed ID: 34532628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms.
    Koschmieder S
    Hamostaseologie; 2020 Feb; 40(1):47-53. PubMed ID: 32050290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review.
    Baysal M; Bayrak M; Eşkazan AE
    Expert Rev Hematol; 2023 Feb; 16(2):131-140. PubMed ID: 36709432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of venous thromboembolism in myeloproliferative neoplasms.
    Barbui T; De Stefano V
    Curr Opin Hematol; 2017 Mar; 24(2):108-114. PubMed ID: 27875375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Splanchnic Vein Thrombosis in Myelofibrosis-An Underappreciated Hallmark of Disease Phenotype.
    Beleva EA
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases.
    Dentali F; Ageno W; Rumi E; Casetti I; Poli D; Scoditti U; Maffioli M; di Minno MN; Caramazza D; Pietra D; De Stefano V; Passamonti F
    Thromb Res; 2014 Jul; 134(1):41-3. PubMed ID: 24787989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.).
    Kreher S; Ochsenreither S; Trappe RU; Pabinger I; Bergmann F; Petrides PE; Koschmieder S; Matzdorff A; Tiede A; Griesshammer M; Riess H; ; ;
    Ann Hematol; 2014 Dec; 93(12):1953-63. PubMed ID: 25307456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Splanchnic vein thrombosis associated with myeloproliferative neoplasms.
    Tremblay D; Winters A; Beckman JD; Naymagon L; Patel R; Mascarenhas J; Schiano TD
    Thromb Res; 2022 Oct; 218():8-16. PubMed ID: 35963121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are MPNs vascular diseases?
    Finazzi G; De Stefano V; Barbui T
    Curr Hematol Malig Rep; 2013 Dec; 8(4):307-16. PubMed ID: 24037420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of Silent Thrombosis in Patients Younger Than 60 Years With Myeloproliferative Neoplasms: Single-Center Egyptian Study.
    Mattar MM; Nassef S; El Husseiny NM; El Masry MR; Salah M; Morad MA; Gawad AA
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e425-e429. PubMed ID: 31229378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.
    Andıç N; Ünübol M; Yağcı E; Akay OM; Yavaşoğlu İ; Kadıköylü VG; Bolaman AZ
    Turk J Haematol; 2016 Sep; 33(3):187-95. PubMed ID: 27094255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management and Outcome of Venous Thrombosis in Patients with Myeloproliferative Neoplasms: Data from the Israeli MPN Working Group.
    Gutwein O; Lavi N; Barzilai M; Shacham-Abulafia A; Leader A; Chubar E; Dally N; Shapira S; Mishchenko E; Ellis M; Koren-Michowitz M
    Acta Haematol; 2021; 144(4):438-445. PubMed ID: 33316809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombotic and bleeding complications in classical myeloproliferative neoplasms.
    McMahon B; Stein BL
    Semin Thromb Hemost; 2013 Feb; 39(1):101-11. PubMed ID: 23264112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.